|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2531 USD | +4.20% |
|
-.--% | - |
| 06-26 | Neuphoria Confirms Business Combination Talks With Scancell | MT |
| 06-26 | Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics | MT |
Evolution of the Average Target: BIONOMICSSADR
Evolution of the Target Price: BIONOMICSSADR
Changes in Analyst Recommendations: BIONOMICSSADR
618713d079ec06afd02a443.trUsCkI1U-XU7Qw6mGfmxJp11crLkDFuT-A2U-IJnfg.w-9LWjNGZqa22UADr1CPlN0mn72N3VlcH6p9H69Krovs0Ftse2ILp5jdRQ~fdaf35437eae1cea6f71841a6b904ee7
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +24.48% | |||||
| +3.57% | |||||
| +17.96% | |||||
| +47.32% | |||||
| +53.12% | |||||
| +11.93% | |||||
| -15.86% | |||||
| +3% | |||||
| +30.47% | |||||
| Average | +19.55% | |||||
| Weighted average by Cap. | +21.65% |
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.400
Average target price
-
Analyst Consensus Detail
Consensus revision (last 18 months)
SellBuy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.400
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NEUP Stock
- BNOX Stock
- Consensus BIONOMICSSADR
Select your edition
All financial news and data tailored to specific country editions
